-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $50

Benzinga·10/21/2026 13:53:36
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $51 to $50.